Evaluation of serum semaphorin-3A and interleukin 6 levels in patients with neovascular age-related macular degeneration

dc.contributor.authorOkutucu, Murat
dc.contributor.authorArpa, Medeni
dc.date.accessioned2026-11-17T06:25:19Z
dc.date.issued2026
dc.departmentRTEÜ, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü
dc.departmentRTEÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü
dc.description.abstractPurpose: To determine whether serum semaphorin 3 A (Sema3A) and interleukin 6 (IL-6) play a role in the common etiopathogenesis of nAMD and nAMD-associated systemic diseases by evaluating these mediators levels. Methods: This prospective case–control study included 74 patients divided into nAMD (n = 33) and a control group (n = 41). Serum Sema3A and IL-6 levels were analyzed using the enzyme-linked immunosorbent assay. Results: The nAMD group had a statistically higher IL-6 level [5,9 (1–16,9) pg/mL], compared to the control group [1,5 (0,38 − 2,96) pg/mL] (p < 0.001). On the other hand, the Sema3A level of the nAMD group was lower at [26,3 (11,5-100) ng/mL] compared to the control group at [44,7 (16,8-100) ng/mL] (p < 0.001). The IL-6 level in the hypertension (+) group [2,5 (0,5–16,9) pg/ml] was significantly higher than that in the hypertension (-) group [1,7 (0,4–15,3) pg/ml] (p < 0.001). No significant difference was found between the hypertension (+) and hypertension (−) groups in terms of SEMA3A level. There was a negative correlation between serum SEMA3A and serum IL-6 levels of the whole participants (p < 0.001, r=-0.471). Conclusions: Decreased levels of the anti-inflammatory and anti-angiogenic mediator Sema3A and increased levels of inflammatory mediator IL-6 detected in nAMD suggest that these molecules may play a role in systemic manifestations of this syndrome, such as inflammation, cardiovascular diseases, atrial fibrillation, and Alzheimer’s disease.
dc.identifier.citationOkutucu, M., & Arpa, M. (2026). Evaluation of serum semaphorin-3A and interleukin 6 levels in patients with neovascular age-related macular degeneration. BMC ophthalmology, 26(1), 634. https://doi.org/10.1186/s12886-026-05128-6
dc.identifier.doi10.1186/s12886-026-05128-6
dc.identifier.issn1471-2415
dc.identifier.issue1
dc.identifier.scopus2-s2.0-105052989814
dc.identifier.scopusqualityQ2
dc.identifier.startpage634
dc.identifier.urihttps://doi.org/10.1186/s12886-026-05128-6
dc.identifier.urihttps://hdl.handle.net/11436/13796
dc.identifier.volume26
dc.indekslendigikaynakScopus
dc.institutionauthorOkutucu, Murat
dc.institutionauthorArpa, Medeni
dc.institutionauthorid0000-0001-8321-4829
dc.language.isoen
dc.publisherBioMed Central Ltd
dc.relation.ispartofBMC Ophthalmology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAlzheimer’s disease
dc.subjectAtrial fibrillation
dc.subjectCardiovascular disease
dc.subjectInflammation
dc.subjectInterleukin 6
dc.subjectNeovascular age related macular degeneration
dc.subjectSemaphorin-3A
dc.titleEvaluation of serum semaphorin-3A and interleukin 6 levels in patients with neovascular age-related macular degeneration
dc.typeArticle

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
okutucu-2026.pdf
Boyut:
1.1 MB
Biçim:
Adobe Portable Document Format

Lisans paketi

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: